当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
John Gilbert
The immunological tolerance of donor-matched transplanted tissues, such as pancreatic islets, can be enhanced by mixed hematopoietic chimerism. Adoption of this approach is, however, constrained by the toxicity of conventional therapies that allow donor hematopoietic cell engraftment. Here, we address these issues by using a non-myeloablative conditioning regimen that promotes allograft tolerance and hematopoietic chimerism across totally mismatched major histocompatibility complex (MHC) barriers. Immunocompetent mice treated with a CD117 antibody that targets the c-Kit protein along with T cell-depleting antibodies and low-dose radiation are able to develop permanent multi-lineage chimerism after hematopoietic cell transplantation. Co-transplantation of donormatched islets and hematopoietic cells effectively reverses diabetes in diabetic mice without causing persistent immunosuppression or significant graft-versus-host disease (GVHD). Allotolerance is most likely mediated by peripheral regulatory T cells produced from the host and donor-derived thymic antigen-presenting cells.